CERO THERAPEUTICS HOLDINGS, INC.
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
CERO | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 201 HASKINS WAY, 94080 SOUTH SAN FRANCISCO
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
CERO Therapeutics Holdings, Inc. is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. The company's core technology is its proprietary Chimeric Engulfment Receptor (CER) T-cell platform. This platform is designed to integrate the anti-tumor capabilities of both the innate and adaptive immune systems into a single T-cell, enabling multiple forms of tumor clearance. CERO's mission is to discover and deliver pioneering curative cell therapies for patients with hematologic malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all CERO THERAPEUTICS HOLDINGS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for CERO THERAPEUTICS HOLDINGS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for CERO THERAPEUTICS HOLDINGS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
